{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:23:34Z","timestamp":1774790614716,"version":"3.50.1"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research Grants Council Collaborative Research Fund","award":["C7156-20G"],"award-info":[{"award-number":["C7156-20G"]}]},{"name":"University Development"},{"name":"Faculty of Medicine Matching","award":["T11-706\/18-N"],"award-info":[{"award-number":["T11-706\/18-N"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been spreading worldwide since December 2019, resulting in the ongoing COVID-19 pandemic with 237 million infections and 4.8 million deaths by 11 October 2021. While there are great efforts of global vaccination, ending this pandemic has been challenged by issues of exceptionally high viral transmissibility, re-infection, vaccine-breakthrough infection, and immune escape variants of concern. Besides the record-breaking speed of vaccine research and development, antiviral drugs including SARS-CoV-2-specific human neutralizing antibodies (HuNAbs) have been actively explored for passive immunization. In support of HuNAb-based immunotherapy, passive immunization using convalescent patients\u2019 plasma has generated promising evidence on clinical benefits for both mild and severe COVID-19 patients. Since the source of convalescent plasma is limited, the discovery of broadly reactive HuNAbs may have significant impacts on the fight against the COVID-19 pandemic. In this review, therefore, we discuss the current technologies of gene cloning, modes of action, in vitro and in vivo potency and breadth, and clinical development for potent SARS-CoV-2-specific HuNAbs.<\/jats:p>","DOI":"10.1093\/immadv\/ltab027","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T13:37:25Z","timestamp":1640871445000},"source":"Crossref","is-referenced-by-count":12,"title":["Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy"],"prefix":"10.1093","volume":"2","author":[{"given":"Dongyan","family":"Zhou","sequence":"first","affiliation":[{"name":"AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong , Pokfulam, Hong Kong Special Administrative Region (SAR) , People\u2019s Republic of China"},{"name":"Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park , Hong Kong SAR , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong , Pokfulam, Hong Kong Special Administrative Region (SAR) , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-8772","authenticated-orcid":false,"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong , Pokfulam, Hong Kong Special Administrative Region (SAR) , People\u2019s Republic of China"},{"name":"State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong , Pokfulam, Hong Kong SAR , People\u2019s Republic of China"},{"name":"Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park , Hong Kong SAR , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"2022062118033620000_CIT0001","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review.","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"2022062118033620000_CIT0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0003","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma.","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"2022062118033620000_CIT0004","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19.","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"Suppl","key":"2022062118033620000_CIT0005","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0092-8674(02)00675-X","article-title":"The mechanism and regulation of chromosomal V(D)J recombination.","volume":"109","author":"Bassing","year":"2002","journal-title":"Cell"},{"key":"2022062118033620000_CIT0006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.nbt.2011.03.014","article-title":"Single B cell antibody technologies.","volume":"28","author":"Tiller","year":"2011","journal-title":"N Biotechnol"},{"key":"2022062118033620000_CIT0007","doi-asserted-by":"crossref","first-page":"11570","DOI":"10.1073\/pnas.1204514109","article-title":"Functional single-cell hybridoma screening using droplet-based microfluidics.","volume":"109","author":"El Debs","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022062118033620000_CIT0008","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/22221751.2019.1614885","article-title":"Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model.","volume":"8","author":"Niu","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"2022062118033620000_CIT0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"2022062118033620000_CIT0010","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1510199112","article-title":"Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.","volume":"112","author":"Corti","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022062118033620000_CIT0011","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"2022062118033620000_CIT0012","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbrc.2012.06.057","article-title":"Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.","volume":"423","author":"Setthapramote","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2022062118033620000_CIT0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.","volume":"329","author":"Tiller","year":"2008","journal-title":"J Immunol Methods"},{"key":"2022062118033620000_CIT0014","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors.","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"2022062118033620000_CIT0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"2022062118033620000_CIT0016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jviromet.2009.02.014","article-title":"High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.","volume":"158","author":"Liao","year":"2009","journal-title":"J Virol Methods"},{"key":"2022062118033620000_CIT0017","doi-asserted-by":"crossref","first-page":"e02002","DOI":"10.1128\/JVI.02002-17","article-title":"Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape.","volume":"92","author":"Wang","year":"2018","journal-title":"J Virol."},{"key":"2022062118033620000_CIT0018","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.","volume":"26","author":"Zost","year":"2020","journal-title":"Nat Med"},{"key":"2022062118033620000_CIT0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells.","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"2022062118033620000_CIT0020","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0021","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.chom.2021.02.019","article-title":"Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.","volume":"29","author":"Zhou","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2022062118033620000_CIT0022","first-page":"95","article-title":"Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.","volume":"3","author":"Zeng","year":"2020","journal-title":"Antib Ther"},{"key":"2022062118033620000_CIT0023","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0024","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/bioinformatics\/btaa739","article-title":"CoV-AbDab: the coronavirus antibody database.","volume":"37","author":"Raybould","year":"2021","journal-title":"Bioinformatics"},{"key":"2022062118033620000_CIT0026","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0027","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0028","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","article-title":"Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.","volume":"538","author":"Yuan","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2022062118033620000_CIT0029","doi-asserted-by":"crossref","first-page":"647934","DOI":"10.3389\/fimmu.2021.647934","article-title":"A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain.","volume":"12","author":"Niu","year":"2021","journal-title":"Front Immunol"},{"key":"2022062118033620000_CIT0030","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","article-title":"Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.","volume":"12","author":"Song","year":"2021","journal-title":"Nat Commun"},{"key":"2022062118033620000_CIT0031","doi-asserted-by":"crossref","first-page":"e01991","DOI":"10.1128\/mBio.01991-20","article-title":"S Protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit.","volume":"11","author":"Nguyen-Contant","year":"2020","journal-title":"mBio."},{"key":"2022062118033620000_CIT0032","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","article-title":"Pan-Sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors.","volume":"385","author":"Tan","year":"2021","journal-title":"N Engl J Med"},{"key":"2022062118033620000_CIT0033","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/22221751.2020.1791738","article-title":"High neutralizing antibody titer in intensive care unit patients with COVID-19.","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022062118033620000_CIT0034","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses.","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"2022062118033620000_CIT0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2022062118033620000_CIT0036","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0037","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa644","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for disease pathogenesis and transmissibility.","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022062118033620000_CIT0038","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.","volume":"368","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0039","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.","volume":"585","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0040","doi-asserted-by":"crossref","first-page":"eabe8146","DOI":"10.1126\/scitranslmed.abe8146","article-title":"Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys.","volume":"13","author":"Speranza","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022062118033620000_CIT0041","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin.","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0042","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment.","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"key":"2022062118033620000_CIT0043","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19.","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0044","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41392-021-00704-2","article-title":"N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding.","volume":"6","author":"Niu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2022062118033620000_CIT0045","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1038\/s41467-021-25903-x","article-title":"Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2.","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"2022062118033620000_CIT0046","article-title":"SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury.","author":"Zhou","year":"2021","journal-title":"bioRxiv"},{"key":"2022062118033620000_CIT0047","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1\u00a0nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0048","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0049","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants.","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"2022062118033620000_CIT0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12916-021-02103-4","article-title":"Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.","volume":"19","author":"Farinholt","year":"2021","journal-title":"BMC Med"},{"key":"2022062118033620000_CIT0051","doi-asserted-by":"crossref","first-page":"2100824","DOI":"10.2807\/1560-7917.ES.2021.26.37.2100824","article-title":"Characterisation of vaccine breakthrough infections of SARS-CoV-2 delta and alpha variants and within-host viral load dynamics in the community, France, June to July 2021.","volume":"26","author":"Blanquart","year":"2021","journal-title":"Eurosurveillance."},{"key":"2022062118033620000_CIT0052","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0053","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"2022062118033620000_CIT0054","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"2022062118033620000_CIT0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"Trial investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19.","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2022062118033620000_CIT0056","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.","volume":"40","author":"Razonable","year":"2021","journal-title":"Eclinicalmedicine"},{"key":"2022062118033620000_CIT0057","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/cells9051267","article-title":"A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping.","volume":"9","author":"Romano","year":"2020","journal-title":"Cells."},{"key":"2022062118033620000_CIT0058","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41577-021-00556-5","article-title":"Will SARS-CoV-2 variants of concern affect the promise of vaccines?","volume":"21","author":"Gupta","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2022062118033620000_CIT0059","first-page":"e2270","article-title":"Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity.","author":"Chakraborty","year":"2021","journal-title":"Rev Med Virol"},{"key":"2022062118033620000_CIT0060","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa.","author":"Pulliam","year":"2021","journal-title":"medRxiv"},{"key":"2022062118033620000_CIT0061","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"Personalized virology initiative study group. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.","volume":"2","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"key":"2022062118033620000_CIT0062","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness.","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"2022062118033620000_CIT0063","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022062118033620000_CIT0064","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022062118033620000_CIT0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2022062118033620000_CIT0066","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"key":"2022062118033620000_CIT0067","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0068","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0069","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0070","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model.","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"2022062118033620000_CIT0071","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection.","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"2022062118033620000_CIT0072","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"2022062118033620000_CIT0073","first-page":"eabc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.","author":"Rogers","year":"2020","journal-title":"Science."},{"key":"2022062118033620000_CIT0074","first-page":"eabc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.","author":"Lv","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0075","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"2022062118033620000_CIT0076","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2.","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltab027\/41986718\/ltab027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/2\/1\/ltab027\/44157624\/ltab027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/2\/1\/ltab027\/44157624\/ltab027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T18:06:20Z","timestamp":1655834780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltab027\/6490058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltab027","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,12,30]]},"article-number":"ltab027"}}